Vesugen: salivary-function adjunctive method — RU2554504C1
Андрей Константинович Иорданишвили, Валерий Валерьевич Лобейко · 2015 · RU2554504C1 · patent family 53498546
Published 2015-06-27.
Reported patent results
Reported findings
Both cases reported more saliva after 30 days; the Vesugen case had the larger numerical increase.
Two different patients with chemotherapy-associated dry mouth: conventional care in one case and conventional care plus branded Vesugen in the other.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Conventional-care case | Saliva collected over 20 minutes: 1.6 → 2.34 mL | One 60-year-old patient · 30 days |
| Vesugen adjunct case | Saliva collected over 20 minutes: 1.3 → 4.3 mL | One 65-year-old patient receiving several treatments · 30 days |
Different patients, cancer locations and baseline values make this an illustrative comparison, not a controlled estimate. Branded capsules do not establish isolated KED efficacy.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. This method describes branded Vesugen during treatment of drug-associated salivary dysfunction.
Branded tablets and concurrent treatment are not evidence for isolated KED, and patent examples may overlap clinical reports.
- Publication
- RU2554504C1 ↗ · 2015-06-27
- Earliest priority / filing
- 2014-02-20 / 2014-02-20
- Original applicant / assignee
- Андрей Константинович Иорданишвили; Валерий Валерьевич Лобейко
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 53498546 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating drug sialoadenopathy
Inventors: Андрей Константинович Иорданишвили; Валерий Валерьевич Лобейко.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Branded tablets and concurrent treatment are not evidence for isolated KED, and patent examples may overlap clinical reports.
- Different patients, cancer locations and baseline values make this an illustrative comparison, not a controlled estimate. Branded capsules do not establish isolated KED efficacy.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-53498546. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Андрей Константинович Иорданишвили, Валерий Валерьевич Лобейко. Vesugen: salivary-function adjunctive method — RU2554504C1 RU2554504C1 · patent family 53498546 2015.
Molekul research summary: https://molekul.io/research/patent-ru2554504c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry